# Binge-Eating Disorder

Diagnose recurrent loss-of-control eating while actively excluding compensatory behaviors and competing eating disorders, then prioritize cognitive behavioral therapy and consider lisdexamfetamine for adults with moderate to severe disease when stimulant risks are acceptable.

**Clinical question:** How should clinicians diagnose and treat adults with binge-eating disorder while selecting and monitoring lisdexamfetamine safely?

Updated: 2026-08-24T18:40:24.839608+00:00

## What matters in practice
- Establish whether recurrent binge eating occurs without extreme compensatory behaviors; compensatory behaviors redirect the diagnosis toward bulimia nervosa or another eating disorder rather than BED.[12][18]
- Use a DSM-5-TR–based clinical diagnostic interview; the EDE-Q or BEDA-Q can support assessment but does not replace diagnostic evaluation.[8]
- Therapist-led CBT improves post-treatment binge-eating abstinence versus waiting list, and CBT is associated with remission of binge eating and purging in 30% to 50% of patients.[9][14]
- Lisdexamfetamine is FDA-indicated for moderate to severe BED in adults; initiate 30 mg each morning and titrate by 20 mg at approximately weekly intervals to 50 to 70 mg daily, maximum 70 mg daily.[2][3]
- Before and throughout lisdexamfetamine treatment, assess and repeatedly monitor misuse, abuse, and addiction risk; it is a Schedule II stimulant with boxed-warning risk for abuse and dependence.[3][5]

## Confirm BED and redirect competing eating-disorder phenotypes

The key diagnostic fork is binge eating with versus without recurrent compensatory behavior.

Conduct a DSM-5-TR–based clinical interview to determine whether episodes involve consumption of a large amount of food in a discrete period with loss of control, then characterize episode frequency, compensatory behaviors, restriction, purging, substance use, mood symptoms, trauma symptoms, and functional impairment. DSM-5-TR clinical assessment remains the preferred diagnostic method for eating disorders; EDE-Q and BEDA-Q are adjunctive self-report measures for structured symptom capture.[8][12]

When recurrent binge eating is accompanied by extreme compensatory behaviors, evaluate for bulimia nervosa rather than BED. BED is characterized by binge eating without extreme compensatory behaviors, whereas binge eating can also occur in bulimia nervosa and anorexia nervosa binge/purge type.[12][18] A lower binge frequency can support an other specified feeding or eating disorder formulation when full bulimia nervosa criteria are not met.[16]

Do not use body size to rule in or rule out BED. Binge-type eating disorders carry psychiatric and physical comorbidity, medication and health-care utilization, and elevated mortality and suicidality risk irrespective of comorbid obesity; the treatment target is loss-of-control eating and associated psychopathology, not weight alone.[12]
- Use the EDE-Q to quantify objective binge episodes and eating-disorder psychopathology longitudinally when a structured self-report measure is useful.[8][12]
- Screen depression with PHQ, generalized anxiety with GAD-7, and assess eating-disorder and other psychiatric diagnoses in the DSM-5-TR interview.[8]
- Ask specifically about trauma and PTSD when clinically indicated; pooled lifetime PTSD prevalence in BED has been reported at 21% to 26%.[23]

*Diagnostic branch points for recurrent binge eating.[8][12][16][18]*

| Clinical finding | Interpretation | Next action |
| --- | --- | --- |
| Recurrent large-volume eating in a discrete period with loss of control; no extreme compensatory behaviors | Consistent with BED phenotype.[12][18] | Complete DSM-5-TR assessment; quantify binge frequency and impairment with interview plus EDE-Q or BEDA-Q if useful.[8] |
| Binge eating plus recurrent extreme compensatory behavior | Redirect toward bulimia nervosa or another binge/purge eating-disorder phenotype.[12][18] | Assess purging and restriction severity and select eating-disorder treatment accordingly. |
| Binge/purge syndrome below full bulimia nervosa frequency threshold | Consider OSFED-bulimia nervosa; lower binge-eating frequency is a primary reason for this classification.[16] | Treat clinically significant binge/purge behavior rather than dismissing subthreshold symptoms. |
| Depression, anxiety, or trauma symptoms accompany binge eating | Psychiatric comorbidity can perpetuate symptoms and modify treatment engagement.[8][23] | Use PHQ and GAD-7 and complete diagnostic assessment for PTSD or other psychiatric disorders when indicated.[8] |

## Make cognitive behavioral therapy the core anti-binge intervention

Psychotherapy directly targets binge eating and should not be deferred solely because weight loss is also desired.

Offer therapist-led cognitive behavioral therapy as a primary treatment for BED. Meta-analytic evidence found greater post-treatment abstinence from binge eating with therapist-led CBT than with waiting-list control, and CBT is associated with remission of binge eating and purging in 30% to 50% of patients, with significant improvement in most others.[9][14]

Set outcomes around binge abstinence or reduction, eating-disorder psychopathology, and functional recovery. CBT and structured self-help approaches, largely CBT-based, have demonstrated benefit for binge-eating outcomes; structured self-help can be considered when therapist-led CBT is inaccessible, but the comparative evidence cited specifically supports therapist-led CBT against waiting list.[9]

Address co-occurring depression, anxiety, and PTSD in the treatment plan rather than assuming that binge remission will resolve all psychiatric symptoms. In BED, PTSD occurs in a substantial minority of patients, and a DSM-5-TR–based psychiatric assessment identifies whether integrated or sequential treatment is required.[8][23]
- Document baseline binge frequency, loss-of-control severity, EDE-Q findings if used, PHQ, and GAD-7 before treatment to permit symptom-based follow-up.[8]
- Reassess whether purging, severe restriction, or other compensatory behaviors emerge during treatment; their presence changes the diagnostic branch away from uncomplicated BED.[12][18]
- Avoid defining psychotherapeutic response solely by weight change; evidence for second-generation antidepressants showed reduced binge eating and eating-disorder psychopathology without weight benefit.[9]

*Treatment choices target different outcomes in BED.[9][13][14]*

| Intervention | Supported treatment effect | Clinical selection point |
| --- | --- | --- |
| Therapist-led CBT | Greater post-treatment abstinence from binge eating than waiting list; remission of binge eating and purging occurs in 30% to 50% of patients.[9][14] | Use as a core treatment when BED symptoms and eating-disorder psychopathology are the primary targets. |
| Structured self-help, mostly CBT-based | Evidence supports improvement in binge-eating outcomes across treatment studies.[9] | Consider when access to therapist-led CBT is limited, with symptom tracking and escalation if inadequate. |
| Second-generation antidepressants | Superior to placebo for post-treatment abstinence, binge-episode reduction, eating-disorder psychopathology, and depression, but not weight.[9] | Consider when depression is clinically relevant or when pharmacotherapy is otherwise appropriate; do not prescribe solely for expected weight loss. |
| Topiramate | Increased abstinence and reduced binge-eating frequency and related psychopathology in systematic-review evidence.[13] | Reserve selection for individualized risk-benefit discussion; this source does not provide a BED dosing regimen. |

## Use lisdexamfetamine selectively for moderate to severe adult BED

Lisdexamfetamine is the FDA-labeled pharmacologic option specifically indicated for moderate to severe BED in adults.

For an adult with moderate to severe BED in whom a stimulant is appropriate, start lisdexamfetamine 30 mg orally once daily in the morning. Increase by 20 mg at approximately weekly intervals to the recommended target range of 50 to 70 mg once daily; do not exceed 70 mg daily. Discontinue treatment if binge eating does not improve.[2][3]

Treat lisdexamfetamine as a controlled-substance decision, not merely a BED medication trial. Before prescribing, assess each patient's risk of abuse, misuse, and addiction; educate the patient and family on secure storage and disposal; then reassess risk and monitor frequently for abuse, misuse, and addiction throughout therapy.[3][5]

Dose-limit lisdexamfetamine in renal impairment: maximum 50 mg once daily with severe renal impairment, defined as GFR 15 to less than 30 mL/min/1.73 m², and maximum 30 mg once daily with end-stage renal disease, defined as GFR below 15 mL/min/1.73 m².[3]
- Monitor for dry mouth, insomnia, decreased appetite, increased heart rate, constipation, jitteriness, and anxiety in adults treated for BED.[5][6]
- If anxiety, insomnia, appetite suppression, or tachycardia materially outweigh anti-binge benefit, reassess the stimulant risk-benefit balance rather than continuing automatically.[5][6]
- Do not extrapolate the BED indication to children or adolescents: FDA labeling identifies BED treatment only in adults, while pediatric approval is for ADHD in patients aged 6 years and older.[1][3][5]

### Selecting medication when psychiatric comorbidity is prominent

When clinically significant depressive symptoms coexist with BED, second-generation antidepressants have evidence for post-treatment binge abstinence, reduced binge episodes, reduced eating-disorder psychopathology, and improvement in depression, but not weight loss.[9] Their role is therefore most coherent when depression is itself a treatment target or stimulant exposure is undesirable.

Topiramate has systematic-review evidence for improving abstinence, binge frequency, and related psychopathology.[13] Because the cited evidence does not provide a treatment dose or selection algorithm, use condition-specific prescribing references before initiating it.

*Lisdexamfetamine dosing and monitoring for adult moderate to severe BED.[2][3][5][6]*

| Decision point | Action | Monitoring or limit |
| --- | --- | --- |
| Initiation | Start 30 mg orally once daily in the morning.[2][3] | Establish baseline binge frequency and assess abuse, misuse, and addiction risk before prescribing.[3] |
| Titration | Increase by 20 mg at approximately weekly intervals to 50 to 70 mg once daily.[2][3] | Maximum 70 mg once daily.[2][3] |
| Response | Continue only if binge eating improves.[2][3] | Discontinue if binge eating does not improve.[2][3] |
| Severe renal impairment | Use no more than 50 mg once daily when GFR is 15 to less than 30 mL/min/1.73 m².[3] | Do not exceed the renal dose cap.[3] |
| End-stage renal disease | Use no more than 30 mg once daily when GFR is below 15 mL/min/1.73 m².[3] | Do not exceed the renal dose cap.[3] |
| Adverse effects and diversion risk | Review insomnia, appetite decrease, increased heart rate, anxiety, jitteriness, dry mouth, and constipation.[5][6] | Frequently reassess for abuse, misuse, addiction, storage, and disposal practices.[3][5] |

## Measure response by binge behavior, diagnostic stability, and medication safety

Follow-up should determine whether the treatment target is improving and whether the original diagnostic branch remains correct.

At each follow-up, record binge-eating days or objective binge episodes, loss-of-control eating, compensatory behaviors, and functional impairment. If using the EDE-Q or BEDA-Q at baseline, repeat the same instrument to track symptom direction; these instruments supplement rather than replace ongoing clinical assessment.[8][12]

For patients receiving lisdexamfetamine, track the labeled common BED adverse effects—dry mouth, insomnia, decreased appetite, increased heart rate, constipation, jitteriness, and anxiety—and reassess stimulant misuse, abuse, and addiction risk throughout treatment.[3][5][6] Stop treatment when binge eating does not improve rather than escalating indefinitely.[2][3]

Escalate diagnostic reassessment when binge eating persists despite adequate treatment exposure, when compensatory behavior appears, or when depression, anxiety, trauma symptoms, or suicidality dominate the presentation. BED has meaningful psychiatric comorbidity and elevated mortality and suicidality risk among binge-type eating disorders, making persistence of high-risk symptoms a reason to broaden treatment rather than simply change the anti-binge medication.[8][12][23]
- A medication response is an anti-binge outcome, not a weight-loss endpoint; antidepressant evidence did not demonstrate weight benefit despite improvement in binge eating and depression.[9]
- A new pattern of recurrent compensatory behavior should trigger reassessment for bulimia nervosa, OSFED, or another eating-disorder phenotype.[12][16][18]
- Persistent trauma-related symptoms merit formal PTSD assessment because PTSD is reported in 21% to 26% of BED populations.[23]

*Follow-up triggers that change the next step.[2][3][8][12][16][18][23]*

| Follow-up finding | Interpretation | Next step |
| --- | --- | --- |
| Fewer binge days or objective binge episodes with improved functioning | Treatment is addressing the anti-binge target.[8][12] | Continue the effective psychotherapy plan or medication regimen while monitoring adverse effects and psychiatric comorbidity. |
| No improvement in binge eating on lisdexamfetamine | The labeled stopping rule has been met.[2][3] | Discontinue lisdexamfetamine and reassess diagnosis, psychotherapy access, comorbidity, and alternative treatment strategy. |
| New purging, fasting, or other extreme compensatory behavior | Presentation no longer fits uncomplicated BED.[12][18] | Reevaluate for bulimia nervosa, OSFED, or another eating disorder.[16] |
| Prominent PTSD, depression, or anxiety symptoms | Psychiatric comorbidity may require concurrent treatment planning.[8][23] | Complete DSM-5-TR–based assessment and direct treatment to the comorbid disorder as well as binge eating.[8] |
| Stimulant adverse effects or emerging misuse concern | Risk may outweigh pharmacologic benefit.[3][5][6] | Reassess continuation, monitoring intensity, and nonstimulant treatment options. |

## References
1. Vyvanse Pediatric Postmarketing Pharmacovigilance and ... — www.fda.gov — https://www.fda.gov/media/142074/download
2. These highlights do not include all the information needed to use VYVANSE safely and effectively.  See full prescribing information for VYVANSE.
       VYVANSE® (lisdexamfetamine dimesylate) capsules, for oral use, CII VYVANSE® (lisdexamfetamine dimesylate) chewable tablets, for oral use, CII Initial U.S. Approval:  2007 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad
3. VYVANSE- lisdexamfetamine dimesylate capsule — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad&type=pdf
4. medication guide — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=da3148af-f9b6-4725-adae-3595b4c7dc4b
5. FDA approves multiple generics of ADHD and BED treatment — www.fda.gov — https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-multiple-generics-adhd-and-bed-treatment
6. LISDEXAMFETAMINE DIMESYLATE CAPSULES
 
      
These highlights do not include all the information needed to use LISDEXAMFETAMINE DIMESYLATE CAPSULES safely and effectively. See full prescribing information for LISDEXAMFETAMINE DIMESYLATE CAPSULES.
 
      
LISDEXAMFETAMINE DIMESYLATE capsules, for oral use, CII
 
Initial U.S. Approval: 2007 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=c91c6acf-b68c-4832-a06f-d0fbd6b80457
7. Supplemental material — ebm.bmj.com — https://ebm.bmj.com/content/ebmed/early/2025/10/08/bmjebm-2025-113759/DC1/embed/inline-supplementary-material-1.pdf?download=true
8. Methodology for studying Relative Energy Deficiency in Sport (REDs): a narrative review by a subgroup of the International Olympic Committee (IOC) consensus on REDs — bjsm.bmj.com — https://bjsm.bmj.com/content/bjsports/57/17/1136.full.pdf
9. Meta-analysis of the effectiveness of psychological and ... — bmjopen.bmj.com — https://bmjopen.bmj.com/content/bmjopen/7/3/e013655.full.pdf
10. Psychiatric and neurological predictors of early ADHD ... — mentalhealth.bmj.com — https://mentalhealth.bmj.com/content/29/1/e302469
11. Psychological interventions to improve glycemic control in adults ... — drc.bmj.com — https://drc.bmj.com/content/bmjdrc/8/1/e001150.full.pdf
12. Mechanism-based subtyping in binge eating: understanding neurobehavioral heterogeneity across negative emotionality, approach behavior, and executive function | Translational Psychiatry — www.nature.com — https://www.nature.com/articles/s41398-025-03408-1
13. Binge-Eating Disorder in Adults: A Systematic Review and ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/M15-2455
14. Eating Disorders | Annals of Internal Medicine — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/AITC202208160
15. Associations Between Posttraumatic Stress Disorder and ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1049386726000423
16. 5 Other Specified Feeding or Eating Disorder‐Bulimia ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/eat.24580
17. Using event-related potentials to study food-related cognition — www.sciencedirect.com — https://www.sciencedirect.com/science/article/am/pii/S0278262622000227
18. Eating disorders — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1357303924001294
19. Mental Health - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/immunology-and-microbiology/mental-health
20. Eating disorders: from bench to bedside and back — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/jnc.13848
21. Binge eating disorder - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9793802
22. Current Status of Evidence for a New Diagnosis: Food Addiction-A Literature Review — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8784968
23. The integrated treatment of eating disorders, posttraumatic stress disorder, and psychiatric comorbidity: a commentary on the evolution of principles and guidelines — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10213703
24. Binge Eating Disorder Is a Social Justice Issue: A Cross-Sectional Mixed-Methods Study of Binge Eating Disorder Experts’ Opinions - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9141064

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.